UPMC Enterprises

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Percipio Health specializes in utilizing artificial intelligence to provide insights that assist clinicians and caregivers in maintaining a comprehensive understanding of a patient's health. The company has developed a platform that enhances the capabilities of computer vision software, allowing healthcare providers to accurately assess patient health status and identify medications. This technology empowers healthcare professionals to make informed decisions regarding patient care, ultimately improving health outcomes.

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Pip Care is a healthcare company that specializes in enhancing the surgical journey through a personalized platform designed for health systems. The company collaborates with these systems to streamline the perioperative care process, supporting care teams and patients from pre-surgery preparation to post-operative recovery. Pip Care offers a dedicated app that empowers patients by providing certified health coaches who create individualized care plans, including daily tasks and tailored advice, helping them manage appointments and feel prepared for their surgeries. By focusing on the digitization and automation of perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of healthcare providers.

Medicom Technologies, Inc. is a North Carolina-based company that provides innovative technology solutions aimed at enhancing patient care. The company addresses interoperability challenges in healthcare by offering a health information network that consolidates clinical data from various sources, improving access to a patient's complete medical history. Its key products include Imagex, a diagnostic image transfer solution; Endpoint, an image archiving system; and Hex, a patient record exchange network. Over 2,000 healthcare organizations utilize Medicom's Network, which replaces traditional methods of information sharing, such as faxes and mailed paperwork, with a more efficient, search-oriented interface. Additionally, Medicom operates the deepMed Marketplace, which supports healthcare data consumers in sectors like life sciences and pharmaceuticals by facilitating the curation of extensive longitudinal data sets for diverse applications, including research and AI development. Founded by Michael Rosenberg, Malcolm Benitz, and Chase Ballard, Medicom continues to advance the integration and usability of health information.

BrainCheck, Inc. specializes in cognitive health solutions for healthcare and athletic organizations in the United States, focusing on assessment and monitoring of cognitive health. The company offers a mobile application compatible with iOS and Android devices that provides tools for individuals to evaluate their cognitive health, particularly concerning issues like concussions and memory changes. This application facilitates the connection between patients and care teams in the concussion and dementia sectors. Users can access interactive tests and screening tools via any mobile device or web browser, allowing for immediate assessment of brain health. Clinicians can track significant changes in cognitive health and share results with patients, thereby enhancing decision-making regarding cognitive health concerns. Founded in 2013, BrainCheck is headquartered in Houston, Texas.

Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.

Elektra Health is a digital healthcare platform designed to support women navigating perimenopause and menopause, addressing the significant challenges many face during this transition. With 80% of women reporting that menopause disrupts their lives due to symptoms such as anxiety, depression, and joint pain, Elektra aims to fill the gap in care, as 75% of those seeking help do not receive adequate support. The platform focuses on destigmatizing menopause and hormones through comprehensive education, community engagement, and access to medical expertise. Elektra provides telemedicine services from board-certified clinicians, an evidence-based educational program, and a private community, empowering women to take control of their hormonal health and improve their quality of life.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Clearsense, LLC is a healthcare technology company based in Jacksonville, Florida, that specializes in providing a cloud-based data platform for the healthcare sector. Founded in 2013, Clearsense offers a comprehensive healthcare analytics and data management solution designed to transform disparate data into a unified source of truth. This platform enables healthcare organizations to gain real-time insights into clinical, operational, and financial metrics, thereby enhancing decision-making and improving overall outcomes. By aggregating and managing data from various sources, Clearsense empowers users to optimize their analytics tools, reduce costs, and identify new revenue opportunities, thereby fostering data confidence and maturity within healthcare organizations.

Smile Digital Health is a health information technology company focused on enhancing global health through innovative data solutions. It offers an enterprise-grade, open-framework data fabric and integration platform specifically designed for the healthcare sector. This platform supports digital transformation by enabling organizations to collaborate effectively and manage health information throughout various patient journeys. By facilitating the ingestion, transformation, storage, enrichment, analysis, and sharing of health data, Smile Digital Health aims to streamline operations and improve outcomes in data-intensive environments.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.

Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Novasenta develops treatments to transform the lives of patients with cancer. It uses systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. The company aims to identify novel targets to generate effective therapies for various cancers. It was founded in 2018 and is headquartered in Pittsburgh, Pennsylvania.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Moxe Health specializes in facilitating the bi-directional exchange of clinical data between health plans and provider systems through its innovative clinical data integration platform. The company offers a range of services including risk adjustment, claims denial management, clinical summaries, administrative notifications, and care gap management. By creating an interactive network, Moxe ensures that health systems and health plans can share medical records and crucial patient insights quickly and efficiently, without disrupting clinicians' existing workflows. The platform supports the transition to value-based care by providing automated solutions that enhance access to essential information, allowing organizations to leverage their investments in population health and analytics effectively. Moxe's commitment to neutrality in data connectivity further enhances its value proposition in the healthcare industry.

Hashed Health is a collaborative healthcare innovation firm that leverages blockchain and distributed ledger technologies to address various challenges in the healthcare sector. The company operates a venture studio aimed at accelerating innovations by partnering with healthcare and life sciences organizations to develop new business models through collaborative efforts. By creating an ecosystem of businesses, Hashed Health facilitates the sharing of clinical, financial, and real-world data assets, enabling efficient asset exchanges and multi-party business process automation. Their initiatives focus on data custody and the development of solutions for complex problems that require collective expertise, drawing on a history of successful healthcare spin-outs.

BrainCheck, Inc. specializes in cognitive health solutions for healthcare and athletic organizations in the United States, focusing on assessment and monitoring of cognitive health. The company offers a mobile application compatible with iOS and Android devices that provides tools for individuals to evaluate their cognitive health, particularly concerning issues like concussions and memory changes. This application facilitates the connection between patients and care teams in the concussion and dementia sectors. Users can access interactive tests and screening tools via any mobile device or web browser, allowing for immediate assessment of brain health. Clinicians can track significant changes in cognitive health and share results with patients, thereby enhancing decision-making regarding cognitive health concerns. Founded in 2013, BrainCheck is headquartered in Houston, Texas.

Smile Digital Health is a health information technology company focused on enhancing global health through innovative data solutions. It offers an enterprise-grade, open-framework data fabric and integration platform specifically designed for the healthcare sector. This platform supports digital transformation by enabling organizations to collaborate effectively and manage health information throughout various patient journeys. By facilitating the ingestion, transformation, storage, enrichment, analysis, and sharing of health data, Smile Digital Health aims to streamline operations and improve outcomes in data-intensive environments.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Moxe Health specializes in facilitating the bi-directional exchange of clinical data between health plans and provider systems through its innovative clinical data integration platform. The company offers a range of services including risk adjustment, claims denial management, clinical summaries, administrative notifications, and care gap management. By creating an interactive network, Moxe ensures that health systems and health plans can share medical records and crucial patient insights quickly and efficiently, without disrupting clinicians' existing workflows. The platform supports the transition to value-based care by providing automated solutions that enhance access to essential information, allowing organizations to leverage their investments in population health and analytics effectively. Moxe's commitment to neutrality in data connectivity further enhances its value proposition in the healthcare industry.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics that enhance the body’s immune response to cancer. Founded in 2017, the company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE molecules. These therapeutics are designed to remain inactive in peripheral tissues but activate selectively within the tumor microenvironment, addressing the limitations of traditional proinflammatory immune therapies. By stimulating both adaptive and innate immunity, Werewolf Therapeutics aims to improve cancer treatment outcomes.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.